Pancreatic cancer blood test study pulled before it began

NCT ID NCT05188573

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a simple blood test could spot early signs of pancreatic cancer in adults aged 50 and older who were recently diagnosed with type 2 diabetes. The plan was to enroll 10,000 participants and follow up with MRI scans for those with a positive test result. However, the study was withdrawn before any volunteers were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

blood test for pancreatic cancer detection

What this could lead to

If validated, this test could help catch pancreatic cancer earlier in people with new-onset diabetes, potentially improving survival odds.

What could go wrong

The study was withdrawn before any participants enrolled, so no data was collected. The test's real-world accuracy and benefit remain unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bluestar Genomics, Inc.

    San Diego, California, 92121, United States